Sanofi and Regeneron Pharmaceuticals Inc. have strengthened the case for using their PCSK9 inhibitor Praluent (alirocumab) to reduce or even eliminate the need for expensive and cumbersome apheresis procedures in patients with heterozygous familial hypercholesterolemia (HeFH) with the presentation of the full results of their ODYSSEY ESCAPE study during a Hotline session at the European Society of Cardiology meeting in Rome this weekend. The data have simultaneously been published in the European Heart Journal.
Both the marketed PCSK9 inhibitors, Praluent and Amgen Inc.'s Repatha (evolocumab), have struggled to gain sales traction in the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
